Építés alatt – nem éles oldal
Belépés
Csak meghívásosFázis nélkül

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

A legfontosabb adatok

Ki végzi
Wake Forest University Health Sciences
Hol
Winston-Salem (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Csak meghívásos
Résztvevők
100 fő, tervezett
Kezdés
2023. ápr. 26.
Várható befejezés
2027. jún.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Non-interventional study
A regiszteradat frissítve
2026. július 14.

Ki vehet részt

Életkor
30 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Egyéb feltételek

  • DM 2 Inclusion Criteria:
  • Age 30-65 years old
  • Diagnosis of DM1 or DM2 is based on genetic testing and/or clinical criteria. If the diagnosis is based on clinical criteria, positive DM2 genetic testing is required in first-degree relatives
  • Symptoms or clinical findings of proximal muscle weakness
  • Ambulate independently (a cane or walking stick is permitted)
  • Able to provide informed consent for participation in the study; DM1 Inclusion Criteria:
  • Only individuals who are 30-65 years old will be eligible to participate for the full study protocol
  • Diagnosis of adult-onset DM1 is based on genetic testing or clinical criteria. If the diagnosis is based on clinical criteria, positive DM1 genetic testing is required in first-degree relatives
  • The onset of first symptoms must be between the 2nd and 4th decades of life
  • Symptoms or clinical findings of distal muscle weakness and myotonia
  • Ambulate independently (a cane or walking stick is permitted)
  • Able to provide informed consent for participation in the study; DM 1 Exclusion Criteria:
  • Congenital or juvenile-onset DM1 (onset of first symptom < 20-year-old)
  • Individuals with a prior diagnosis of dementia, seizure, stroke, multiple sclerosis, Parkinson's Disease, or other neurodegenerative diseases
  • Individuals with active psychiatric illness or alcohol/substance abuse
  • On medications with substantial sedative or cognitive side effects unless the doses have been stable for at least 3 months before the study visit
  • Inability or unwillingness to give written informed consent; DM 1 and 2 and Healthy Control (HC) Exclusion Criteria:
  • Individuals with a pacemaker, defibrillator, or metal implanted that is contraindicated for MRI
  • Individuals who are claustrophobic
  • Individuals with a prior diagnosis of dementia, seizure, stroke, multiple sclerosis, Parkinson's Disease, or other neurodegenerative diseases
  • Individuals with active psychiatric illness, alcohol or substance abuse, or dependence
  • Individuals with a pacemaker, defibrillator, or metal implanted that is contraindicated for MRI
  • Individuals who are claustrophobic
  • Major medical illness which would prevent safe testing of MRI or motor function
  • On medications with substantial sedative or cognitive side effects unless the doses have been stable over the last 3 months before the study visit
  • pregnancy
  • Weight > 400 pounds as the participant could not be properly positioned on the MRI table
  • Inability or unwillingness to give written informed consent
  • For participants who undergo lumbar puncture procedure: Use of anti-platelet medications within 7 days, use of anticoagulants such as warfarin (Coumadin), history of a bleeding disorders, evidence of platelet count < 150,000 within the last 6 months, or have hardware (i.e., pins, screws, rods, etc.) in the lower back area; Healthy Control (HC) Inclusion Criteria:
  • Age 30-65 years
  • Ambulate independently
  • Able to provide informed consent for participation in the study

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 30 és 65 év között vagy?

Helyszínek itt: Egyesült Államok

  • Wake Forest University Health SciencesWinston-Salem, Egyesült ÁllamokCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life. Yet, relatively little is known about how DM2 affects brain structure and cognitive function as brain imaging studies in DM2 are extremely limited. This is a prospective, cross-sectional study of brain structure and function on cognitive and motor performance in patients with DM2 \& DM1 compared to healthy controls. All participants will undergo magnetic resonance imaging (MRI) to evaluate brain structure and white matter integrity, a comprehensive battery of cognitive and motor measures, self-reported questionnaires, and blood collection for brain-based biomarker analysis. A subset of participants will undergo lumbar puncture for cerebrospinal fluid (CSF) collection for additional biomarker analysis and validation. This work is critical to inform the development of rigorous clinical trial designs and plan for a longitudinal study to evaluate MRI measures as imaging biomarkers of disease progression and therapeutic response in DM2 \& DM1.

A vizsgálat 2 csoportja

  • Myotonic dystrophy types 1 and 2

    Adults with myotonic dystrophy types 1 and 2 who meet all inclusion and exclusion criteria for the study. To be assessed at the baseline visit: Medical history and a focused neurological examination, brain MRI, a comprehensive Clinical Assessment Battery (CAB) of cognitive and motor measures, self-reported questionnaires, strength and motor function evaluation, and blood drawn for biomarker analysis. A subset of the participants who agree to have cerebrospinal fluid (CSF) collection for additional biomarker analysis will undergo lumbar puncture procedure.

    Kezelés: Non-interventional study

  • Controls

    Healthy individuals who meet all inclusion and exclusion criteria for healthy controls. To be assessed at the baseline visit: Medical history and a focused neurological examination, brain MRI, a comprehensive Clinical Assessment Battery (CAB) of cognitive and motor measures, self-reported questionnaires, strength and motor function evaluation, and blood drawn for biomarker analysis. A subset of the participants who agree to have cerebrospinal fluid (CSF) collection for additional biomarker analysis will undergo lumbar puncture procedure.

    Kezelés: Non-interventional study

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2 (BraCE-DM2)
Illeszkedési kérdések
Forrás: NCT05854433: ki vehet részt
A regiszteradat frissítve
2026. július 14.